|Date||November 4, 2013|
|Time||4:30 pm EST|
|Telephone access: U.S. and Canada||800-619-2686|
|Telephone access: International||303-223-4363|
|Live webcast||www.therapeuticsmd.com (see Investor tab)|
The portfolio has outperformed the Russell 2000 index by more than 400 basis points, year to date.
Trade-Ideas LLC identified TherapeuticsMD (TXMD) as a weak on high relative volume candidate
Biotechs are leading, which tells me there's enough speculative interest.
TherapeuticsMD (TXMD) stock is spiking Monday afternoon after the company announced strong hormone therapy trial results.